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Abstract 
Background. It's unclear whether pre-transplant T. gondii seropositivity is associated with impaired survival 
in heart transplant recipients. 
Objectives. To test the above-mentioned hypothesis in the Spanish Heart Transplantation Registry. 
Methods. Post-transplant outcomes of 4048 patients aged > 16 years who underwent first, single-organ heart 
transplantation in 17 Spanish institutions from 1984 to 2014 were studied. Long-term post-transplant survival 
and survival free of cardiac death or retransplantation of 2434 (60%) T. gondii seropositive recipients and 
1614 (40%) T. gondii seronegative recipients were compared. 
Results. T. gondii seropositive recipients were older, had higher body mass index, and presented higher 
prevalence of hypertension, hypercholesterolemia, COPD and Cytomegalovirus seropositivity than T. gondii 
seronegative recipients. In univariable analysis, pre-transplant T. gondii seropositivity was associated with 
increased post-transplant all-cause mortality (non-adjusted HR 1.15; 95% CI 1.04–1.26). However, this effect 
was no longer statistically significant after multivariable adjustment by recipient's age and sex (adjusted HR 
1.01, 95% CI 0.92–1.11). Extended multivariable adjustment by other potential confounders showed similar 
results (adjusted HR 0.99, 95% CI 0.89–1.11). T. gondii seropositivity had no significant effect on the 
composite outcome cardiac death or retransplantation (non-adjusted HR 1.08, 95% CI 0.95–1.24, p = 0.235). 
The distribution of the causes of death was comparable in T. gondii seropositive and T. gondii seronegative 
recipients. No statistically significant impact of donor's T. gondii serostatus or donor-recipient T. gondii 
serostatus matching on post-transplant survival was observed. 
  
Conclusions. Our analysis did not show a significant independent effect of preoperative T. gondii serostatus 
on long-term outcomes after heart transplantation. 
Abbreviations 
CAV, coronary allograft vasculopathy; CI, confidence interval; HR, hazard ratio; HT, heart transplantation; 
TG, Toxoplasma gondii 
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1. Background 
Over the past 10 years, there has been an unsolved controversy about the potential influence of 
Toxoplasma gondii (TG) serostatus of heart transplantation (HT) recipients on their long-term 
outcomes after the operation [1]. A pioneer retrospective report from a Norwegian center [2] 
showed a striking reduction of late post-transplant survival among TG seropositive recipients as 
compared with seronegative ones, which was attributed to an increased incidence of advanced 
coronary allograft vasculopathy (CAV). Enhancement of several immune responses triggered by 
chronic TG infection was proposed as a hypothetical explanation for these intriguing findings. 
 
The validity of the Norwegian analysis was openly questioned due to inconsistencies in the 
statistical methodology used to assess confusion bias [3]. Later on, three subsequent single-center 
studies failed to confirm an independent effect of TG serostatus on post-transplant outcomes [4–
6]; moreover, one study reported increased early post-transplant mortality among TG seronegative 
recipients [7]. Until now, no significant influence of either donor's TG serostatus or donor-
recipient TG serostatus matching on post-transplant outcomes has been proven [2,4–6]. 
 
Given the discrepancies among previously published single-center studies, we aimed to 
investigate a potential impact of recipient's TG serostatus on long-term post-transplant survival in 
the multi-institutional cohort of the Spanish Heart Transplantation Registry [8]. 
2. Methods 
2.1. Study description 
The Spanish Heart Transplantation Registry is a prospective database promoted by the 
Working Group in Heart Failure of the Spanish Society of Cardiology that contains detailed 
clinical information about all HT procedures performed in our nation since 1984 to present. The 
registry is updated in a yearly basis with data supplied by all transplant centers of the country. This 
database has been described elsewhere [8]. 
 
For the present study, we selected from the Spanish Heart Transplantation Registry database all 
patients aged > 16 years who underwent first, single-organ, orthotopic HT in Spain until December 
31st, 2014, for whom reliable information about their pre-transplant TG serostatus was available. 
Vital status as of December 31st, 2015 was known for all subjects. 
 
Baseline clinical characteristics and long-term post-transplant survival of TG seropositive and 
TG seronegative recipients were compared. Pre-transplant TG seropositivity was defined by the 
detection of specific immunoglobulin G against the parasite, according to local diagnostic 
protocols of participating hospitals. This investigation was approved by the Local Committee for 
Ethics in Clinical Research of A Coruña-Ferrol, Department of Healthcare, Autonomous 
Community of Galicia (Spain).  
2.2. End-points 
Long-term survival after HT was the primary end-point of the study. The composite outcome 
cardiac death or cardiac re-transplantation was a secondary end-point. 
 
Cardiac death was defined as any death attributable to heart failure, myocardial ischemia or 
arrhythmia, including deaths secondary to acute rejection, CAV, or primary or unexplained graft 
dysfunction. For survival analysis, sudden deaths and deaths from an unknown origin were also 
assumed as cardiac deaths. 
2.3. Statistical analysis 
In this manuscript, continuous variables are presented as mean ± standard deviation or median 
(interquartile rank), depending on whether they follow a normal distribution, and categorical 
variables are presented as proportions. Baseline clinical characteristics of TG seropositive and TG 
seronegative recipients were compared by means of the chi-squared test, the T-student test or the 
Mann-Whitney test, as required. 
 
Non-adjusted long-term post-transplant survival curves of TG seropositive and TG 
seronegative recipients were constructed with the Kaplan-Meier method and compared with the 
log rank test. 
 
Cox's multivariable models were used to control the influence of confusion bias on the 
statistical effect of recipient's TG serostatus on long-term post-transplant survival. A first 
multivariable model (Model 1) including recipient's age, recipient's gender and recipient's TG 
serostatus was constructed in order to adjust the statistical effect of TG seropositivity on survival 
by demographic factors. Further adjustment was performed by means of an extended multivariable 
model (Model 2), which included several baseline variables additional to demographic factors, 
which were considered by the investigators as potential confounders. A confounder was defined as 
a baseline variable showing an asymmetric distribution between TG seropositive and TG 
seronegative patients, together with either a statistical significant association with post-transplant 
survival in the study population or a consistent association with post-transplant survival in 
previous literature. Covariables selected for extended multivariable adjustment (Model 2) were age 
of the recipient, gender of the recipient, body mass index, diabetes, hypertension, ischemic heart 
disease, Cytomegalovirus serostatus, age of the donor, mechanical circulatory support, mechanical 
ventilation, tacrolimus use, mophetil mycophenolate use, transplant era, and cold ischemic time. 
Adjusted long-term post-transplant survival curves for TG seropositive and TG seronegative 
recipients were estimated by means of both multivariable models [1 and 2]. 
 
In the subpopulation of subjects for whom both recipient's and donor's TG serostatus were 
known, we performed an exploratory analysis about a potential influence of donor-recipient TG 
serostatus matching on long-term post-transplant survival, by using the Kaplan-Meier method and 
multivariable Cox's regression. For this analysis, patients were divided in four categories 
according to donor-recipient TG serostatus matching, as follows: donor (+)/recipient (+), donor 
(+)/recipient (−), donor (−)/recipient (+), and donor (−)/recipient (−). The donor (+)/recipient (+) 
subgroup was considered as the reference category for statistical comparisons. 
 
Statistical analysis was performed with Stata 12. Statistical significance was set as a p value 
< 0.05 for all tests. 
  
3. Results 
3.1. Patients 
From 1984 to 2014, 7277 patients underwent first, single-organ, orthotopic HT in 17 Spanish 
institutions, 4048 of which constituted the study population. Reasons for exclusion were 
age < 16 years (n = 390), re-transplantation (n = 164), multi-organ transplantation (n = 124) and 
the lack of information about recipient's pre-transplant TG serostatus (n = 2533). Before HT, 2434 
(60%) study patients were TG seropositive and 1614 (40%) were TG seronegative. 
3.2. Baseline clinical characteristics 
The Table 1 shows a comparison of baseline clinical characteristics of TG seropositive and TG 
seronegative recipients. At the time of HT, TG seropositive recipients were significantly older, had 
higher body mass index and higher prevalence of cardiovascular risk factors like hypertension and 
hypercholesterolemia, and more frequently presented chronic obstructive pulmonary disease and 
Cytomegalovirus seropositivity than TG seronegative recipients. 
 
The need for preoperative mechanical ventilation and mechanical circulatory support was more 
frequent among TG seronegative recipients; cold ischemic times were also longer in these 
individuals. 
 
The use of tacrolimus and mycophenolate mophetil as part of the initial immunosuppressive 
regimen was less frequent among TG seropositive recipients, which in a higher proportion were 
transplanted during the older era (1984–2000). 
  
Table 1. Baseline clinical characteristics of T. gondii seronegative recipients and T. gondii seropositive recipients. 
 
Toxoplasma gondii seropositive 
recipients 
N = 2434 
Toxoplasma gondii 
seronegative recipients 
N = 1614 
p 
    
Recipients 
   
 Age (years), mean ± standard deviation 54.9 ± 9.6 48.7 ± 12.9 < 0.001 
 Body mass index 26 ± 3.9 25 ± 4.1 < 0.001 
 Women 18.1% 22.7% < 0.001 
 Transplant era 
  
< 0.001 
 1984–2000 30.2% 24.2% 
 
 2001–2014 69.8% 75.8% 
 
 Ischemic heart disease 32.9% 30.1% 0.065 
 History of smoking 20.2% 19.5% 0.638 
 Diabetes mellitus 16.2% 14.3% 0.112 
 Hypertension 34.4% 28.1% < 0.001 
 Hypercholesterolemia 41.2% 34.3% < 0.001 
 Previous cardiac surgery 23.5% 21.6% 0.166 
 Cytomegalovirus seropositive recipient 86.1% 74.2% < 0.001 
 Previous malignancy 3.5% 4.4% 0.153 
 Chronic obstructive pulmonary disease 12.5% 8.3% < 0.001 
 Inotropic therapy 29.6% 34.7% 0.001 
 Mechanical circulatory support 17.6% 22.5% 0.003 
 Dialysis 8.3% 9.1% 0.435 
 Mechanical ventilation 9.5% 12.5% 0.004 
 Renal dysfunctiona 16% 17.2% 0.329 
 Liver dysfunctionb 17.3% 16.8% 0.690 
 Mean pulmonary pressure (mm Hg) 30.1 ± 10.6 30.3 ± 10.6 0.371 
 Pulmonary vascular resistance (Wood units) 2.4 ± 2.2 2.2 ± 1.3 0.066 
Donors 
   
 Cold ischemic time (min) 184.8 ± 64.7 191.0 ± 65.8 0.009 
 Women 30.4% 33.6% 0.034 
 Body mass index (kg/m2) 25.2 ± 3.6 25.1 ± 3.6 0.289 
 Age (years) 35.9 ± 13.3 35.8 ± 13.2 0.719 
Baseline immunosuppression 
   
 Corticosteroids 98% 97.1% 0.506 
 Cyclosporine A 63.6% 55.6% < 0.001 
 Tacrolimus 31.9% 39.8% < 0.001 
 Mycophenolate mophetil 64.5% 70.4% < 0.001 
 Azathioprine 32.8% 25.5% < 0.001 
 Sirolimus 1.4% 1.2% 0.575 
 Everolimus 1.8% 2.4% 0.224 
    
 
a Serum creatinin > 2 mg/dl. 
b Serum bilirrubin > 2 mg/dl. 
  
3.3. Causes of death 
Median follow-up after HT was 2103 days (interquartile rank 568 to 4153 days). Over this 
period, 1903 (47%) patients died, of which 1215 were TG seropositive and 688 were TG 
seronegative before HT. Also, 79 (2%) patients underwent cardiac re-transplantation, of which 48 
were TG seropositive and 31 were TG seronegative before their first HT. 
 
The presumed cause of death was cardiac in 616 (32%) deceased patients and non-cardiac in 
1038 (55%) deceased patients; in the remaining 249 (13%) deceased patients, it was unknown. The 
distribution of the causes of death among TG seronegative recipients and TG seropositive 
recipients showed no relevant differences, as detailed in the Table 2. 
Table 2. Distribution of the causes of death of T. gondii seropositive recipients and T. gondii seronegative recipients. 
 
T. gondii seronegative 
recipients 
N = 688 
T. gondii seropositive 
recipients 
N = 1215 
   
Cardiac 233 (34%) 383 (32%) 
 Graft failure, postoperative 76 119 
 Graft failure, acute rejection 29 37 
 Graft failure, coronary allograft vasculopathy 26 62 
 Graft failure, non-specified 36 58 
 Sudden death 66 107 
Non-cardiac 364 (53%) 674 (55%) 
 Multi-organ failure 109 128 
 Infection 65 162 
 Malignancy 47 117 
 Other 143 267 
Unkwnown 91 (13%) 158 (13%) 
   
 
3.4. Primary end-point: all-cause death 
Kaplan-Meier long-term post-transplant survival curves of TG seropositive and TG 
seronegative recipients are depicted in Fig. 1. TG seropositive recipients had shorter non-adjusted 
survival than seronegative ones (non-adjusted hazard ratio (HR) 1.15; 95% Confidence Interval 
(CI) 1.04–1.26; log rank p < 0.001). Non-adjusted post-transplant all-cause mortality rates were 
62.6 (95% CI 58.1–67.5) deaths per 1000 patients-year among TG seronegative recipients and 
70.2 (95% CI 66.4–74.3) deaths per 1000 patients-year among TG seropositive ones. 
  
 
 
 
Fig. 1. Kaplan-Meier analysis of long-term post-transplant survival of T. gondii 
seropositive recipients (blue line) and T. gondii seronegative recipients (red line). TG, 
Toxoplasma gondii. 
The statistical effect of TG serostatus on long-term post-transplant survival was no longer 
statistically significant after multivariable adjustment (Supplementary Table 1). By means of the 
multivariable model 1, which included the demographic factors age and sex of the recipient as co-
variables, the estimated HR for death for TG seropositive recipients vs. TG seronegative ones was 
1.01 (95% CI 0.92–1.11, p = 0.842). 
 
Extended multivariable adjustment was conducted by means of multivariable model 2, which 
included several potential confounders additionally to demographic factors, but no significant 
change of the results was obtained. By means of the model 2, the estimated HR for death for TG 
seropositive recipients vs. TG seronegative ones was 0.99 (95% CI 0.89–1.11, p = 0.925). 
 
Adjusted long-term post-transplant survival functions of TG seropositive recipients and TG 
seronegative recipients, as estimated by means of Cox's multivariable models 1 and 2, are 
represented graphically in Fig. 2. 
  
 
 
 
Fig. 2. Adjusted survival functions of T. gondii seropositive recipients (blue line) and T. 
gondii seronegative recipients (red line), as estimated by means of Cox's proportional 
hazards regression. Panel A, Multivariable model 1 (age- and sex-adjusted survival). Panel 
B, Multivariable model 2 (extended multivariable adjustment). 
3.5. Secondary end-point: cardiac death or cardiac re-transplantation 
Univariable analysis did not reveal a statistically significant association between TG 
seropositivity and the risk of the composite outcome cardiac death or cardiac re-transplantation 
(non-adjusted HR 1.08, 95% CI 0.95–1.24; p = 0.235). Non-adjusted incidence rates of the 
secondary end-point were 32.1 (95% CI 29.0–35.7) events per 1000 patients-year among TG 
seronegative recipients and 34.1 (95% CI 31.4–36.9) events per 1000 patients-year among TG 
seronegative ones. 
 
Neither multivariable adjustment by age and sex of the recipient (Model 1: adjusted HR 1.08, 
95% CI 0.95–1.24; p = 0.231) nor by other potential confounders (Model 2: adjusted HR 1.04, 
95% CI 0.88–1.22; p = 0.650) led to a significant change of the result. 
  
3.6. Donor-recipient T. gondii serostatus matching 
Donor's TG serostatus was known in 1975 (49%) recipients. Among them, 559 (28%) were 
donor (+)/recipient (+), 302 (15%) were donor (+)/recipient (−), 620 (32%) were donor 
(−)/recipient (+) and 493 (25%) were donor (−)/recipient (−). 
 
Regardless donor's TG serostatus, TG seronegative recipients showed a trend to higher non-
adjusted post-transplant survival than seronegative ones; however, differences across four 
categories of donor-recipient TG serostatus matching did not reach statistical significance (p log 
rank = 0.083, Supplementary Fig. 1). 
 
Considering the donor (+)/recipient (+) subgroup as the reference category, age- and sex-
adjusted HR (Model 1) for post-transplant all-cause mortality in the donor (+)/recipient (−), donor 
(−)/recipient (+) and donor (−)/recipient (−) subgroups were 0.92 (95% CI 0.73–1.15; p = 0.448), 
1.04 (95% CI 0.87–1.23; p = 0.676), and 1.02 (95% CI 0.84–1.24; p = 0.835), respectively. 
Extended multivariable adjustment (Model 2) showed similar results. 
4. Discussion 
To the best of our knowledge, this is the first multi-institutional study to address the hypothesis 
that pre-transplant TG seropositivity is a risk factor for mortality in HT recipients. By using a 
previously collected dataset of > 4000 patients who received a heart graft in Spain over the last 
30 years, we failed to demonstrate an independent impact of pre-transplant TG serostatus on post-
transplant survival. Neither a significant effect of donor-recipient TG serostatus matching on post-
transplant outcomes was observed. 
 
Since the early eras of transplantation, doctors taking care of transplant recipients are 
concerned about the possibility of opportunistic infections in such patients. T. gondii is an 
intracellular parasite, for which the human body constitutes a secondary host. In immune 
competent subjects, the clinical course of TG infection is usually oligosymptomatic, as the parasite 
is efficiently cleared by cellular immunity. However, in the setting of cellular immunodeficiency, 
TG infection may lead to severe clinical consequences, mainly at the central nervous system. 
Primary infection of a never before exposed subject carries the highest risk of complications; this 
is the reason why TG serostatus is routinely tested during the selection process of HT candidates, 
and why primary chemoprophylaxis against TG is usually administered to TG seronegative 
patients who receive a graft from a TG seropositive donor [9]. 
 
Approximately 10 years ago, there was a change in how transplant doctors regard the clinical 
implications of TG exposure in HT recipients. A striking study based on 288 individuals who 
underwent HT at a single Norwegian institution reported a strong increase of late post-transplant 
mortality among TG seropositive recipients in comparison with TG seronegative ones [2]. This 
finding was attributed to an increased incidence of advanced CAV and death due to this condition. 
To explain their results, the authors hypothesized that chronic TG infection might contribute to the 
development of CAV and graft dysfunction through the enhancement of several immunological 
responses, as endothelial cell activation, cytokine overexpression and T-helper cell activation 
[2,10–11]. Until now, these pathophysiological mechanisms remain essentially speculative, as no 
consistent proofs of a causal association between TG exposure and the development of CAV have 
been presented. 
 
Later on, a few subsequent single-center studies addressed this intriguing topic, but all failed to 
reproduce earlier findings [4–6]. In their univariable analysis based on 582 patients who 
underwent cardiac transplantation since 1984 to 2011 in a Dutch center, Van Hellemond et al. [4] 
also reported reduced non-adjusted long-term post-transplant survival in TG seropositive 
recipients; however, after multivariable adjustment, the effect of TG serostatus on survival was no 
longer statistically significant. A Spanish group [5] reached similar conclusions by analyzing the 
long-term post-transplant outcomes of 657 patients who received a heart graft since 1991 to 2014; 
in this study, a moderately increased risk of acute rejection was observed among TG seropositive 
recipients, but this fact did not carry a significant impact on survival. Another single-centre 
American study focused on 785 patients who underwent HT between 1995 and 2012, showing no 
significant impact of pre-transplant TG serostatus on post-transplant survival [6]. More conflicting 
results were reported by Doesch et al. [7], who described increased early postoperative mortality 
among TG seronegative recipients in their analysis based on 344 patients transplanted since 1989 
to 2008 in a German institution. 
 
Similarly to described in other studies [4,5], TG seropositive recipients of our multi-
institutional cohort presented shorter non-adjusted long-term post-transplant survival than TG 
seronegative recipients in univariable analysis. However, this statistically significant, negative 
effect of pre-transplant TG seropositivity on post-transplant survival was lost after a simple 
multivariable adjustment by baseline demographic factors –age and sex of the recipient–. A more 
complex multivariable adjustment, which included several additional covariables selected by study 
investigators as potential confounders, did not result in a relevant change in the sense of the result. 
 
Our findings suggest that confusion bias is the most probable explanation for the hypothesized 
association between pre-transplant TG serostatus and post-transplant outcomes. The prevalence of 
TG exposure, and so, TG seropositivity, is directly related to age [12]. In our series, TG 
seropositive recipients were, as an average, > 6 years older than TG seronegative ones at the time 
of HT. As a result, TG seropositive recipients presented a higher prevalence of adverse clinical 
conditions related to age, as cardiovascular risk factors, chronic obstructive pulmonary disease and 
CMV seropositivity. This reality was similar in previous studies [2,4,5]. 
 
A glance to the Kaplan-Meier long-term post-transplant survival curves of TG seropositive and 
TG seronegative recipients only reveals a clear separation between them at late follow-up. In our 
opinion, this fact reflects the impact of the unbalanced baseline distribution of age and co-
morbidities in both study groups on long-term post-transplant survival. Interestingly, adjusted HR 
for all-cause mortality estimated by two different multivariable models were very close to 1, 
indicating a consistent neutral effect of TG serostatus on survival. This constitutes a strong 
argument to affirm that the proposed association between TG serostatus and post-transplant 
outcomes is probably spurious, rather than causal. 
 
Due to the lack of data, we could not compare the incidence of new-onset CAV or acute 
rejection in TG seropositive and TG seronegative recipients. Nevertheless, neither univariable nor 
multivariable analyses revealed a statistically significant difference between both groups with 
regard to the risk of the composite end-point cardiac death or cardiac re-transplantation, which is 
an appropriate surrogate for those graft-related adverse clinical events. To date, only one study 
described an excess of CAV-related mortality in TG seropositive recipients [2]; other authors [4–
5,7], like us, did not observe any relevant difference with regard to the distribution of the causes of 
death according to pre-transplant TG serostatus. 
 
Our analysis did not show a significant impact of donor's TG serostatus or donor-recipient TG 
serostatus matching on post-transplant outcomes. This conclusion may be regarded with caution, 
given that recipient's TG serostatus was only known in 49% patients of our population. 
Nonetheless, this finding is also consistent with previous studies [2,4–7]. The lack of a negative 
prognostic effect of a TG seropositive donor in a TG seronegative recipient has been proposed as 
an argument against a causal association between TG serostatus and post-cardiac transplant 
outcomes [1]. 
 
Our study has a few limitations. As a retrospective one, it is exposed to potential selection and 
information biases inherent to this type of investigation. Comprehensive multivariable adjustment 
was conducted in order to control the effect of potential confounders; however, we cannot rule out 
categorically that any other non-tested variable may have influenced observed statistical 
associations. The study addressed a heterogeneous population, as it involved several hospitals 
across Spain, with different center-specific protocols regarding post-transplant chemoprophylaxis 
and infection surveillance. It is remarkable that our analysis excluded near 45% HT recipients 
enrolled in the Spanish Heart Transplant Registry; the lack of reliable information about their 
preoperative TG serology was the reason for exclusion in most cases. The lack of information 
about evolutionary TG serology prevented us to analyze the incidence of TG new infection or 
reactivation over post-transplant follow-up. Specific information about the type, duration and 
compliance of TG chemoprophylaxis was not available. Given the long period studied, a 
significant era effect cannot be excluded; notwithstanding this, no relevant changes in the 
association between TG serostatus and post-transplant outcomes was observed when transplant era 
was entered as a covariable in multivariable models constructed for statistical adjustment. 
5. Conclusions 
In conclusion, our study showed a statistically significant, moderate reduction of non-adjusted 
long-term survival after orthotopic HT among recipients who showed a positive serostatus against 
TG before the intervention, as compared with seronegative ones. However, the effect of 
preoperative TG seropositivity on post-transplant survival remained neutral after multivariable 
adjustment, both in a simple model which only included recipient's age and sex as co-variables, 
and also in an extended model which added several other potential confounders. Our data suggest 
that the hypothesized association between recipient's TG serostatus and long-term post-transplant 
survival is, rather than causal, more probably explained by confusion bias derived by an older age 
at the time of HT and a higher prevalence of comorbidities among seropositive recipients. 
Therefore, this study does not support any specific change in the standard clinical management of 
TG seropositive individuals undergoing orthotopic HT. 
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